Clinical trial
Combination Chemotherapy and Rituximab in Treating Patients With Untreated…
NCT00433537 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00433537 |
|---|---|
| Title | Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma |
| Official title | A Phase II Study of VcR-CVAD With Rituximab Maintenance for Untreated Mantle Cell Lymphoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Stage I Mantle Cell Lymphoma, Stage III Mantle Cell Lymphoma, Stage IV Mantle Cell Lymphoma |
| Intervention type | Biological, Drug, Procedure |
| Interventions | bortezomib, rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, dexamethasone, filgrastim, pegfilgrastim, Autologous stem cell transplantation (ASCT) |
| Enrollment | 77 |
| Start date | May 1, 2007 |
| Primary completion | Jun 1, 2013 |
| Completion | Jun 1, 2013 |
| First posted | Feb 12, 2007 |
| Last update posted | Oct 30, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: